Successful treatment of severe juvenile microscopic polyangiitis with rituximab

被引:9
作者
Brunner, J. [1 ]
Freund, M. [2 ]
Prelog, M. [1 ]
Binder, E. [1 ]
Sailer-Hoeck, M. [1 ]
Jungraithmayr, T.
Huemer, C. [4 ]
Sergi, C. [3 ]
Zimmerhackl, L. B.
机构
[1] Innsbruck Med Univ, Dept Paediat, A-6020 Innsbruck, Austria
[2] Innsbruck Med Univ, Dept Radiol, A-6020 Innsbruck, Austria
[3] Innsbruck Med Univ, Inst Pathol, A-6020 Innsbruck, Austria
[4] Bregenz Childrens Hosp, Bregenz, Austria
关键词
Children; Microscopic polyangiitis; Rituximab; Vasculitis; SYSTEMIC-LUPUS-ERYTHEMATOSUS; VASCULITIS; GRANULOMATOSIS;
D O I
10.1007/s10067-009-1177-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Microscopic polyangiitis (MPA) previously called hypersensitivity angiitis is a systemic necrotizing vasculitis affecting predominantly small vessels. MPA involves multiple organ systems including the lung, the kidneys, the joints, and the skin. MPA mostly affects adults in their fourth and fifth decade of life. MPA and Wegener`s granulomatosis are grouped together as ANCA-associated vasculitis. MPA is associated with high titre of myeloperoxidase antineutrophil cytoplasmic antibodies (MPO)-ANCA. We present a 14-year-old female patient presented with MPA. She was treated with steroids and cyclophosphamide. After the complication of severe lung involvement, rituximab was administered as immune-modulating treatment. The MPA came to remission. This is the first report of a pediatric patient with MPA treated with rituximab. Rituximab might be a potential therapeutic option for relapsing ANCA associated vasculitis in childhood.
引用
收藏
页码:997 / 999
页数:3
相关论文
共 15 条
[1]   Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression - Case report [J].
Edelbauer, M ;
Jungraithmayr, T ;
Zimmerhackl, LB .
PEDIATRIC NEPHROLOGY, 2005, 20 (06) :811-813
[2]   Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases [J].
El-Hallak, Moussa ;
Binstadt, Bryce A. ;
Leichtner, Alan M. ;
Bennett, Carolyn M. ;
Neufeld, Ellis J. ;
Fuhlbrigge, Robert C. ;
Zurakowski, David ;
Sundel, Robert P. .
JOURNAL OF PEDIATRICS, 2007, 150 (04) :376-382
[3]   Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab [J].
Eriksson, P .
JOURNAL OF INTERNAL MEDICINE, 2005, 257 (06) :540-548
[4]   Challenges in the management of microscopic polyangiitis: past, present and future [J].
Jayne, David .
CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (01) :3-9
[5]  
Minami Rumi, 2007, Nihon Rinsho Meneki Gakkai Kaishi, V30, P133
[6]   EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides [J].
Ozen, S ;
Ruperto, N ;
Dillon, MJ ;
Bagga, A ;
Barron, K ;
Davin, JC ;
Kawasaki, T ;
Lindsley, C ;
Petty, RE ;
Prieur, AM ;
Ravelli, A ;
Woo, P .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) :936-941
[7]   Rituximab for Severe Refractory Pediatric Wegener Granulomatosis [J].
Patel, Aarat M. ;
Lehman, Thomas J. A. .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2008, 14 (05) :278-280
[8]   Childhood microscopic polyangiitis associated with MPO-ANCA [J].
Peco-Antic, A ;
Bonaci-Nikolic, B ;
Basta-Jovanovic, G ;
Kostic, M ;
Markovic-Lipkovski, J ;
Nikolic, M ;
Spasojevic, B .
PEDIATRIC NEPHROLOGY, 2006, 21 (01) :46-53
[9]   Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis - Remission, relapse, and re-treatment [J].
Smith, K. G. C. ;
Jones, R. B. ;
Burns, S. M. ;
Jayne, D. R. W. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2970-2982
[10]   Consensus statement on the use of rituximab in patients with rheumatoid arthritis [J].
Smolen, J. S. ;
Keystone, E. C. ;
Emery, P. ;
Breedveld, F. C. ;
Betteridge, N. ;
Burmester, G. R. ;
Dougados, M. ;
Ferraccioli, G. ;
Jaeger, U. ;
Klareskog, L. ;
Kvien, T. K. ;
Martin-Mola, E. ;
Pavelka, K. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (02) :143-150